Cargando…

Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study

BACKGROUND: Steroid pulse (SP) therapy is one of the immunosuppressive therapies for immunoglobulin A nephropathy (IgAN). Although there are various protocols of SP therapy in IgAN, the intermittent SP (ISP) and consecutive SP (CSP) protocols are prevalently performed in clinical settings. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamatani, Satoshi, Kono, Keiji, Fujii, Hideki, Hirabayashi, Ken, Shimizu, Mao, Watanabe, Kentaro, Goto, Shunsuke, Nishi, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016979/
https://www.ncbi.nlm.nih.gov/pubmed/35436909
http://dx.doi.org/10.1186/s12882-022-02791-x
_version_ 1784688675051798528
author Yamatani, Satoshi
Kono, Keiji
Fujii, Hideki
Hirabayashi, Ken
Shimizu, Mao
Watanabe, Kentaro
Goto, Shunsuke
Nishi, Shinichi
author_facet Yamatani, Satoshi
Kono, Keiji
Fujii, Hideki
Hirabayashi, Ken
Shimizu, Mao
Watanabe, Kentaro
Goto, Shunsuke
Nishi, Shinichi
author_sort Yamatani, Satoshi
collection PubMed
description BACKGROUND: Steroid pulse (SP) therapy is one of the immunosuppressive therapies for immunoglobulin A nephropathy (IgAN). Although there are various protocols of SP therapy in IgAN, the intermittent SP (ISP) and consecutive SP (CSP) protocols are prevalently performed in clinical settings. However, there is a lack of evidence of comparisons of the effects on IgAN between these two protocols. METHODS: A total of 189 patients with IgAN who had received SP therapy were included in this study. They were divided into two groups according to the SP protocols into the intermittent SP (ISP) or consecutive SP (CSP) group as follows: ISP; three-times SP therapy in alternate months, CSP; three-times SP therapy in three consecutive weeks. Kidney function, remission of urinary findings, and side effects of SP therapy were compared between the two groups. The observational period was 12 months after the initiation of SP therapy. RESULTS: There was no significant difference in kidney function between the two groups during the observational period. The remission rate of proteinuria and hematuria at 12 months also did not significantly differ between the two groups. Furthermore, even after the adjustment of clinical characteristics using propensity score matching, the remission rate of proteinuria and hematuria at 12 months was similar between the two groups. At 2 months, the remission rate of proteinuria was significantly higher in the CSP group than in the ISP group. There were no critical side effects in both groups. CONCLUSION: The effects of SP therapy on IgAN were similar between the ISP and CSP group at 12 months although CSP therapy could remit proteinuria faster than ISP therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-022-02791-x.
format Online
Article
Text
id pubmed-9016979
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90169792022-04-20 Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study Yamatani, Satoshi Kono, Keiji Fujii, Hideki Hirabayashi, Ken Shimizu, Mao Watanabe, Kentaro Goto, Shunsuke Nishi, Shinichi BMC Nephrol Research BACKGROUND: Steroid pulse (SP) therapy is one of the immunosuppressive therapies for immunoglobulin A nephropathy (IgAN). Although there are various protocols of SP therapy in IgAN, the intermittent SP (ISP) and consecutive SP (CSP) protocols are prevalently performed in clinical settings. However, there is a lack of evidence of comparisons of the effects on IgAN between these two protocols. METHODS: A total of 189 patients with IgAN who had received SP therapy were included in this study. They were divided into two groups according to the SP protocols into the intermittent SP (ISP) or consecutive SP (CSP) group as follows: ISP; three-times SP therapy in alternate months, CSP; three-times SP therapy in three consecutive weeks. Kidney function, remission of urinary findings, and side effects of SP therapy were compared between the two groups. The observational period was 12 months after the initiation of SP therapy. RESULTS: There was no significant difference in kidney function between the two groups during the observational period. The remission rate of proteinuria and hematuria at 12 months also did not significantly differ between the two groups. Furthermore, even after the adjustment of clinical characteristics using propensity score matching, the remission rate of proteinuria and hematuria at 12 months was similar between the two groups. At 2 months, the remission rate of proteinuria was significantly higher in the CSP group than in the ISP group. There were no critical side effects in both groups. CONCLUSION: The effects of SP therapy on IgAN were similar between the ISP and CSP group at 12 months although CSP therapy could remit proteinuria faster than ISP therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-022-02791-x. BioMed Central 2022-04-18 /pmc/articles/PMC9016979/ /pubmed/35436909 http://dx.doi.org/10.1186/s12882-022-02791-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yamatani, Satoshi
Kono, Keiji
Fujii, Hideki
Hirabayashi, Ken
Shimizu, Mao
Watanabe, Kentaro
Goto, Shunsuke
Nishi, Shinichi
Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title_full Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title_fullStr Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title_full_unstemmed Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title_short Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
title_sort comparison of two protocols for steroid pulse therapy in patients with iga nephropathy: a retrospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016979/
https://www.ncbi.nlm.nih.gov/pubmed/35436909
http://dx.doi.org/10.1186/s12882-022-02791-x
work_keys_str_mv AT yamatanisatoshi comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT konokeiji comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT fujiihideki comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT hirabayashiken comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT shimizumao comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT watanabekentaro comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT gotoshunsuke comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy
AT nishishinichi comparisonoftwoprotocolsforsteroidpulsetherapyinpatientswithiganephropathyaretrospectiveobservationalstudy